LALC_Capital
$SRTA Strata Critical Medical authorized a 20M share buyback with Q3 results. Revenue was 74.1M, up 50.3% from 49.3M, mostly from acquisitions; pro forma growth was 8.5%. Adjusted EBITDA 9.6M (13.0% margin) vs 4.2M, and free cash flow 8.6M, which the company called a record.
The offset: net loss from continuing operations was 7.6M, and Logistics revenue fell 3.5%. 2026 guidance reiterated at 285-295M revenue.
Filing: https://www.sec.gov/Archives/edgar/data/1779128/000162828026069117/srta-earningreleasexq32026.htm
1
